Kyverna Q2 net loss $28.8M; cash $346.2M; RMAT designations for KYV-101

Kyverna Therapeutics, Inc.

2024-Q2 EPS reported -$1.66

Q2 net loss $28.8M ($0.67 per share) vs $13.1M loss year ago.
Cash, equivalents & marketable securities $346.2M as of June 30, 2024.
No severe ICANS or CRS Grade ≥3 in 36 autoimmune patients treated with KYV-101.
100% manufacturing success for KYV-101 across 36 patients.
Received FDA RMAT designations for Stiff-Person Syndrome and Myasthenia Gravis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.